Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.
John T Miura, Jonathan S Zager
https://pubmed.ncbi.nlm.nih.gov/31538818/Actively Recruiting
Led by Philogen S.p.A. · Updated on 2025-12-17
186
Participants Needed
37
Research Sites
208 weeks
Total Duration
Researchers are evaluating the effectiveness of Daromun, a neoadjuvant intratumoral treatment, combined with surgery and adjuvant therapy compared to surgery and adjuvant therapy alone in patients with Stage IIIB, IIIC, or IIID melanoma. The study aims to determine if Daromun can significantly improve recurrence-free survival RFS in these patients. This is a Phase 3, open-label, randomized, controlled, multi-center trial involving 186 participants. Participants will be randomly assigned to one of two groups Arm 1 will receive Daromun injections directly into melanoma lesions once weekly for up to four weeks, followed by surgery within four weeks and then adjuvant therapy. Arm 2 will undergo surgery within four weeks after randomization followed by adjuvant therapy. Post-surgery adjuvant therapies are decided by the investigator and may include immunotherapy or targeted treatments. Throughout the study, participants will be followed for up to five years to assess recurrence-free survival, with additional survival data collected up to six years after randomization. Safety assessments include monitoring adverse events, laboratory tests, electrocardiograms, echocardiograms, physical exams, and vital signs. Tumor response will be evaluated during surgery. Participants will attend scheduled visits for treatment, monitoring, and follow-up to evaluate both the primary and secondary outcomes.
CONDITIONS
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
S
Sheila Dakhel, PhD
C
Concetta Aulicino
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Philogen S.p.A.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Neoadjuvant Daromun + Surgery + Adjuvant Therapy | Surgery + Adjuvant Therapy |
|---|---|---|
| What is it? | Neoadjuvant (pre-surgery) intratumoral Daromun injections are given to target melanoma lesions, followed by complete surgical resection and standard adjuvant therapy. | Standard care involving complete surgical resection of all resectable melanoma lesions, followed by adjuvant therapy such as immunotherapy or targeted therapy at the investigator's discretion. |
| Role in the trial | Study intervention being evaluated for improved outcomes as neoadjuvant therapy before surgery. | Comparator group representing current guideline-recommended approach: surgery plus adjuvant therapy. |
| Primary use or purpose | Intended to reduce recurrence risk and improve clinical outcomes by inducing tumor response prior to surgery. | Aims to surgically remove all visible melanoma, followed by adjuvant treatment to lower the chance of recurrence. |
| How is it given or performed? | Daromun is injected directly into melanoma lesions once weekly for up to 4 weeks, followed by surgery and adjuvant systemic therapy as decided by the investigator. | Patients undergo surgical removal of all detectable melanoma lesions. Adjuvant systemic therapy (for example, immune checkpoint inhibitors or BRAF/MEK inhibitors) is administered post-operatively based on clinical guidelines. |
| Evidence status | Effectiveness and long-term outcomes are under investigation in this randomized trial. Published data for neoadjuvant Daromun are currently limited. | Surgery followed by adjuvant immune checkpoint inhibitors or BRAF/MEK inhibitors (when indicated) is well-established and supported by large trials showing improved recurrence-free and overall survival for stage III melanoma. |
| Important limitations | Clinical experience and evidence for neoadjuvant Daromun are still limited; long-term outcomes and comparative safety remain under investigation in this large randomized study. | While surgery and adjuvant therapy are established, recurrence can still occur and not all patients can tolerate standard adjuvant treatments. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 weeks
Participants in the experimental arm receive weekly intratumoral Daromun injections for up to 4 weeks before surgery. Participants in the control arm proceed directly to surgery within 4 weeks of randomization.
Weekly visits for up to 4 weeks for Daromun administration; surgery visit within 4 weeks from randomization
Duration - Up to 4 weeks
Participants undergo surgery to remove melanoma tumors, followed by immediate post-operative care.
1 surgery visit and post-operative care visits as needed
Duration - Variable duration as per standard of care
Participants receive adjuvant therapy as decided by their investigator after surgery to help prevent melanoma recurrence.
Visit frequency depends on the specific adjuvant therapy administered
Duration - Up to 6 years
Participants are followed up for recurrence-free survival and overall survival for up to 6 years after randomization to monitor health and disease status.
Regular visits over several years for long-term follow-up assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
John T Miura, Jonathan S Zager
https://pubmed.ncbi.nlm.nih.gov/31538818/Claire Gorry, Laura McCullagh, Helen O'Donnell...
https://pubmed.ncbi.nlm.nih.gov/36648215/Philogen S.p.A.
Lead Sponsor